 This study is designed to provide efficacy and safety data in patients with choroidal neovascularisation CNV secondary to myopia using an individualized as-needed PRN dosing schedule. Eligible patients who have provided written agreement to take part in the study will receive an intravitreal into the study eye injection of ranibizumab 0.5mg. Following eye examinations and tests at monthly clinic visits, the study doctor will repeat the injections on a monthly basis as required for an additional 11 months, in accordance with specified retreatment criteria. 